Wuhan Healthgen Biotechnology Corp. (SHA:688765)
China · Delayed Price · Currency is CNY 78.58
+0.62 (0.80%)
At close: Dec 5, 2025
SHA:688765 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 28.82 | 25.22 | 23.47 | 12.82 | 24.84 | 19.68 | Upgrade |
Other Revenue | -0.42 | - | 0.79 | 0.58 | 0.68 | 1.89 | Upgrade |
| 28.39 | 25.22 | 24.26 | 13.4 | 25.52 | 21.57 | Upgrade | |
Revenue Growth (YoY) | 17.02% | 3.92% | 81.08% | -47.49% | 18.33% | 110.40% | Upgrade |
Cost of Revenue | 10.19 | 9.21 | 12.2 | 5.31 | 9.9 | 6.26 | Upgrade |
Gross Profit | 18.21 | 16.01 | 12.06 | 8.09 | 15.62 | 15.3 | Upgrade |
Selling, General & Admin | 71.52 | 63.35 | 58.84 | 58.99 | 71.31 | 32.84 | Upgrade |
Research & Development | 110.92 | 116.79 | 159.1 | 110.5 | 75.21 | 45.05 | Upgrade |
Other Operating Expenses | -25.13 | -17.39 | 1.77 | 0.77 | 0.28 | 0.15 | Upgrade |
Operating Expenses | 157.67 | 162.75 | 219.72 | 170.26 | 146.8 | 78.05 | Upgrade |
Operating Income | -139.47 | -146.74 | -207.66 | -162.17 | -131.18 | -62.74 | Upgrade |
Interest Expense | - | -2.88 | -0.66 | -0.23 | -0.53 | -0.97 | Upgrade |
Interest & Investment Income | 3.1 | - | 5.79 | 14.64 | 2.73 | 0.3 | Upgrade |
Currency Exchange Gain (Loss) | 0.02 | - | -0.13 | 0.39 | -0.06 | -0.5 | Upgrade |
Other Non Operating Income (Expenses) | -7.51 | - | -0.02 | 0 | -0.09 | -0.04 | Upgrade |
EBT Excluding Unusual Items | -143.85 | -149.61 | -202.68 | -147.36 | -129.13 | -63.95 | Upgrade |
Gain (Loss) on Sale of Assets | 2.91 | -1.28 | 1.01 | 0.33 | -11.27 | 2.08 | Upgrade |
Asset Writedown | -0.85 | -0.48 | -0 | -0.87 | 0 | - | Upgrade |
Legal Settlements | - | - | - | -1.49 | - | - | Upgrade |
Other Unusual Items | -12.62 | - | 14.71 | 5.82 | 6.36 | 8.52 | Upgrade |
Pretax Income | -154.4 | -151.37 | -186.96 | -143.58 | -134.04 | -53.35 | Upgrade |
Net Income | -154.4 | -151.37 | -186.96 | -143.58 | -134.04 | -53.35 | Upgrade |
Net Income to Common | -154.4 | -151.37 | -186.96 | -143.58 | -134.04 | -53.35 | Upgrade |
Shares Outstanding (Basic) | 271 | 270 | 267 | 261 | 216 | 50 | Upgrade |
Shares Outstanding (Diluted) | 271 | 270 | 267 | 261 | 216 | 50 | Upgrade |
Shares Change (YoY) | 1.41% | 1.20% | 2.31% | 20.75% | 333.57% | 4.84% | Upgrade |
EPS (Basic) | -0.57 | -0.56 | -0.70 | -0.55 | -0.62 | -1.07 | Upgrade |
EPS (Diluted) | -0.57 | -0.56 | -0.70 | -0.55 | -0.62 | -1.07 | Upgrade |
Free Cash Flow | -408.29 | -220.38 | -224.45 | -424.7 | -263.44 | -36.85 | Upgrade |
Free Cash Flow Per Share | -1.51 | -0.81 | -0.84 | -1.63 | -1.22 | -0.74 | Upgrade |
Gross Margin | 64.12% | 63.49% | 49.71% | 60.40% | 61.21% | 70.95% | Upgrade |
Operating Margin | -491.20% | -581.92% | -855.82% | -1210.22% | -514.08% | -290.94% | Upgrade |
Profit Margin | -543.81% | -600.28% | -770.53% | -1071.48% | -525.26% | -247.39% | Upgrade |
Free Cash Flow Margin | -1438.01% | -873.96% | -925.01% | -3169.44% | -1032.38% | -170.86% | Upgrade |
EBITDA | - | -99.64 | -160.56 | -149.78 | -121.52 | -52.63 | Upgrade |
EBITDA Margin | - | - | - | - | - | -244.06% | Upgrade |
D&A For EBITDA | - | 47.1 | 47.1 | 12.38 | 9.67 | 10.11 | Upgrade |
EBIT | -139.47 | -146.74 | -207.66 | -162.17 | -131.18 | -62.74 | Upgrade |
EBIT Margin | - | - | - | - | - | -290.94% | Upgrade |
Advertising Expenses | - | - | 0.12 | 0.07 | 0.13 | 0 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.